C V Fletcher

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Concentration-controlled compared with conventional antiretroviral therapy for HIV infection
    Courtney V Fletcher
    Department of Experimental and Clinical Pharmacology, University of Minnesota Academic Health Sciences Center, Minneapolis, MN, USA
    AIDS 16:551-60. 2002
  2. ncbi Food affects Zidovudine concentration independent of effects on gastrointestinal absorption
    Themba T Ndovi
    Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University, Baltimore, MD 21287, USA
    J Clin Pharmacol 47:1366-73. 2007
  3. ncbi Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection
    Courtney V Fletcher
    Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Pharmacotherapy 24:453-9. 2004
  4. ncbi Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count
    Courtney V Fletcher
    Clinical Pharmacy and Infectious Diseases, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
    Drugs 67:1969-79. 2007
  5. ncbi Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 189:1176-84. 2004
  6. ncbi Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 40:301-6. 2005
  7. ncbi Enfuvirtide, a new drug for HIV infection
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Lancet 361:1577-8. 2003
  8. ncbi Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial
    C V Fletcher
    Division of Infectious Diseases, Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Pharmacol Ther 83:300-6. 2008
  9. ncbi Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma
    D W Haas
    Division of Infectious Diseases, Department of Medicine and Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    AIDS Res Hum Retroviruses 16:1491-502. 2000
  10. ncbi The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
    J J Kiser
    School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA
    Clin Pharmacol Ther 83:265-72. 2008

Detail Information

Publications55

  1. ncbi Concentration-controlled compared with conventional antiretroviral therapy for HIV infection
    Courtney V Fletcher
    Department of Experimental and Clinical Pharmacology, University of Minnesota Academic Health Sciences Center, Minneapolis, MN, USA
    AIDS 16:551-60. 2002
    ..To demonstrate the feasibility of a concentration-controlled approach to combination antiretroviral therapy, and to compare the virological responses and safety of this strategy versus conventional fixed-dose therapy...
  2. ncbi Food affects Zidovudine concentration independent of effects on gastrointestinal absorption
    Themba T Ndovi
    Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University, Baltimore, MD 21287, USA
    J Clin Pharmacol 47:1366-73. 2007
    ..This effect may be due to the increased hepatic metabolism because feeding increases hepatic blood flow and because ZDV has a high hepatic extraction ratio with low affinity to blood plasma proteins...
  3. ncbi Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection
    Courtney V Fletcher
    Pediatric AIDS Clinical Trials Group and the Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    Pharmacotherapy 24:453-9. 2004
    ..To evaluate and describe the parameters and characteristics of different drug regimens in children infected with human immunodeficiency virus (HIV)...
  4. ncbi Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count
    Courtney V Fletcher
    Clinical Pharmacy and Infectious Diseases, University of Colorado Health Sciences Center, 4200 East 9th Avenue, Denver, CO 80262, USA
    Drugs 67:1969-79. 2007
    ..A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV...
  5. ncbi Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Infect Dis 189:1176-84. 2004
    ..42%; adjusted odds ratio, 0.43). In this study, a greater proportion of females had HIV RNA levels </=500 copies/mL than did males, which can be attributed to higher concentrations of saquinavir in females than in males...
  6. ncbi Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 40:301-6. 2005
    ..Self-reported adherence and saquinavir AUC were significant predictors of virologic response, in this evaluation. These findings provide insight into methods of assessing and improving adherence to antiretroviral regimens...
  7. ncbi Enfuvirtide, a new drug for HIV infection
    Courtney V Fletcher
    Department of Clinical Pharmacy, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Lancet 361:1577-8. 2003
  8. ncbi Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial
    C V Fletcher
    Division of Infectious Diseases, Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, Colorado, USA
    Clin Pharmacol Ther 83:300-6. 2008
    ..Dose adjustment to achieve specific AUC values in these children reduced the risk of suboptimal exposure and achieved high rates of virologic suppression...
  9. ncbi Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma
    D W Haas
    Division of Infectious Diseases, Department of Medicine and Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee 37212, USA
    AIDS Res Hum Retroviruses 16:1491-502. 2000
    ..This study supports the utility of ultraintensive CSF sampling for studying HIV-1 pathogenesis and therapy in the CNS, and provides strong evidence that HIV-1 RNA in CSF arises, at least in part, from a source other than plasma...
  10. ncbi The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients
    J J Kiser
    School of Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, Colorado, USA
    Clin Pharmacol Ther 83:265-72. 2008
    ..Future studies should clarify the exact mechanism and whether there is an increased risk of nephrotoxicity...
  11. ncbi Concentration-controlled zidovudine therapy
    C V Fletcher
    Division of Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, USA
    Clin Pharmacol Ther 64:331-8. 1998
    ..The active moiety of nucleoside anti-HIV drugs is the intracellular anabolite. Therefore the heterogeneity in response to nucleoside agents may arise as a result of pharmacologic variability at both the systemic and cellular level...
  12. ncbi Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS
    H H Balfour
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA
    Antimicrob Agents Chemother 40:2721-6. 1996
    ..The dual antiviral activity of foscarnet shown in this trial encourages investigation of its use in combination with other antiretroviral therapies for persons with AIDS...
  13. ncbi Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
    E P Acosta
    College of Pharmacy, Department of Experimental and Clinical Pharmacology, University of Minnesota Academic Health Sciences Center, Minneapolis, MN 55455, USA
    Clin Infect Dis 30:S151-9. 2000
    ..However, prospectively designed clinical trials must be completed to determine if monitoring protease inhibitor plasma concentrations provides additional clinical benefit to the patient...
  14. ncbi Pharmacologic considerations for therapeutic success with antiretroviral agents
    C V Fletcher
    Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis 55455, USA
    Ann Pharmacother 33:989-95. 1999
    ..To explore pharmacologic elements that contribute to therapeutic success with agents used for the treatment of HIV infection...
  15. ncbi Simultaneous HPLC assay for quantification of indinavir, nelfinavir, ritonavir, and saquinavir in human plasma
    R P Remmel
    Departments of Medicinal Chemistry and Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Chem 46:73-81. 2000
    ..Dual protease inhibitor therapy is also being used clinically. Consequently, a simultaneous assay for indinavir, nelfinavir, ritonavir, and saquinavir was developed...
  16. ncbi Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults
    Peter L Anderson
    University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    AIDS 21:1849-54. 2007
    ..The objective of this study was to determine whether concentrations of ZDV-TP and 3TC-TP in PBMC reflect the concentrations within CD4 T cells in HIV-seronegative adults...
  17. ncbi Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS
    Tom Delahunty
    Antiviral Pharmacology Laboratory, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, 80262, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 830:6-12. 2006
    ..The usefulness of this LC/MS/MS method to routinely monitor plasma concentrations of TNF was demonstrated along with its ability to assist in the performance of pharmacokinetic studies...
  18. ncbi Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study
    Heather J Ribaudo
    Statistical Data Analysis Center, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    Clin Infect Dis 42:401-7. 2006
    ..Lower plasma efavirenz clearance is associated with a cytochrome P450 2B6 gene (CYP2B6) polymorphism (516G-->T) that is more frequent among African American individuals than among European American individuals...
  19. ncbi Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology
    Tracy King
    Antiviral Pharmacology Laboratory, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Box C238, 4200 East 9th Avenue, Denver, CO 80262, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 831:248-57. 2006
    ..The assay correlated well with a previous ELISA method developed and validated in our laboratory, and has been successfully used to quantitate ZDV-TP concentrations in patients being routinely monitored and treated with ZDV...
  20. ncbi Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection
    Jennifer J Kiser
    Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Pharmacotherapy 26:511-4. 2006
    ....
  21. ncbi Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy
    Akihiko Saitoh
    Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla 92093-0672, USA
    J Allergy Clin Immunol 117:909-15. 2006
    ..Thus, a thymic control mechanism is required to maintain new CD4+ T lymphocytes in the presence of persistent virus. CLINICAL IMPLICATIONS: The TREC level is a useful marker of thymic function in HIV-infected children...
  22. ncbi Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms
    Christina L Aquilante
    University of Colorado at Denver and Health Sciences Center, School of Pharmacy, Department of Clinical Pharmacy, Denver, CO 80262, USA
    Clin Chim Acta 372:195-8. 2006
    ..We designed a multiplex genotyping assay to detect the CYP3A5(*)3C and CYP3A5(*)6 polymorphisms in a single polymerase chain reaction (PCR) and a single pyrosequencing reaction...
  23. ncbi Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study
    Peter L Anderson
    University of Colorado at Denver and Health Sciences Center, Denver, CO 80262, USA
    J Acquir Immune Defic Syndr 42:441-9. 2006
    ..The aim of the study was to investigate relationships among indinavir, lamivudine-triphosphate, and zidovudine-triphosphate pharmacokinetics and pharmacodynamics with polymorphisms in CYP3A5, MDR1, MRP2, MRP4, BCRP, and UGT1A1 genes...
  24. ncbi Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells
    Tracy King
    Antiviral Pharmacology Laboratory, Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Health Sciences Center, Box C238, 4200 East 9th Avenue, Denver, CO 80262, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 843:147-56. 2006
    ..This paper outlines the development and validation of the determination of TFV-DP concentrations in femtomoles per million hPBMCs...
  25. ncbi Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection
    Jennifer J Kiser
    University of Colorado at Denver and Health Sciences Center, Denver, CO, USA
    Antimicrob Agents Chemother 52:631-7. 2008
    ..Additional studies of the exposure-response relationships of this regimen in children, adolescents, and adults would advance our knowledge of its pharmacodynamic properties...
  26. ncbi Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression
    Susan Swindells
    Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5400, USA
    JAMA 296:806-14. 2006
    ..Maintenance therapy with ritonavir-boosted atazanavir alone is a possible option because of low pill burden, once-daily dosing, safety, and unique resistance profile...
  27. ncbi Impact of nucleoside reverse transcriptase inhibitors on mitochondria in human immunodeficiency virus type 1-infected children receiving highly active antiretroviral therapy
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0672, USA
    Antimicrob Agents Chemother 51:4236-42. 2007
    ..This may be of particular importance in resource-limited countries where didanosine is widely used for the treatment of HIV-infected children...
  28. ncbi Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093 0672, USA
    J Acquir Immune Defic Syndr 45:280-5. 2007
    ..The impact of CYP2B6-G516T polymorphisms on EFV concentrations may be different in children because of differences in liver maturation and drug dosage...
  29. ncbi Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359
    Richard H Haubrich
    University of California San Diego, San Diego, California 92103, USA
    HIV Clin Trials 8:63-7. 2007
    ....
  30. ncbi The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection
    David M Margolis
    University of North Carolina at Chapel Hill, 3302 Michael Hooker Research Center, Chapel Hill, NC 27599, USA
    AIDS 21:2025-32. 2007
    ..We evaluated the safety, tolerability and antiretroviral activity of beta-D-2,6-diaminopurine dioxolane (DAPD; amdoxovir) with or without mycophenolate mofetil (MMF) in HIV-1 infection following extensive antiretroviral therapy (ART)...
  31. ncbi Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients
    Jennifer J Kiser
    School of Pharmacy, University of Colorado at Denver, Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:298-303. 2008
    ..Nucleos(t)ide reverse transcriptase inhibitors (NRTIs), such as tenofovir, require intracellular phosphorylation for pharmacologic activity. Drug transporters may contribute to the intracellular disposition of NRTIs...
  32. ncbi Updated clinical pharmacologic considerations for HIV-1 protease inhibitors
    Peter L Anderson
    Division of Clinical Pharmacology, University of Colorado Health Science Center, Box C237, 4200 East 9th Ave, Denver, CO 80262, USA
    Curr HIV/AIDS Rep 1:33-9. 2004
    ..In the future, dosing strategies that accommodate the variability in pharmacokinetics and pharmacodynamics may improve virologic outcomes...
  33. ncbi Intrapatient variability of efavirenz concentrations as a predictor of virologic response to antiretroviral therapy
    Richard C Brundage
    University of Minnesota, Minneapolis, Minnesota, USA
    Antimicrob Agents Chemother 48:979-84. 2004
    ..This novel method for the quantitation of intrapatient concentration variability was independently predictive of virologic rebound. This measure may allow interventions to minimize therapeutic failure and is applicable to other drugs...
  34. ncbi Pharmacology considerations for antiretroviral therapy in human immunodeficiency virus (HIV)-infected children
    Dorie W Hoody
    Antiviral Pharmacology Laboratory, School of Pharmacy, University of Colorado Health Sciences Center, Denver, 80206, USA
    Semin Pediatr Infect Dis 14:286-94. 2003
    ....
  35. ncbi Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals
    Peter L Anderson
    Antiviral Pharmacology Laboratory, School of Pharmacy, University of Colorado Health Sciences Center, Denver 80262, USA
    AIDS 17:2159-68. 2003
    ....
  36. ncbi Efavirenz liquid formulation in human immunodeficiency virus-infected children
    Stuart E Starr
    Division of Infectious and Immunologic Diseases, Abramson Research Center, The Children s Hospital of Philadelphia, PA 19104, USA
    Pediatr Infect Dis J 21:659-63. 2002
    ....
  37. ncbi Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359
    Roy M Gulick
    Weill Medical College of Cornell University, New York, New York 10021, USA
    J Infect Dis 186:626-33. 2002
    ..These results show that some patients who experience treatment failure can demonstrate durable virologic and immunologic responses with salvage antiretroviral regimens...
  38. ncbi Clinical implications of CNS penetration of antiretroviral drugs
    Heather E Wynn
    Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, Minnesota, USA
    CNS Drugs 16:595-609. 2002
    ..Prospective, controlled studies examining this relationship are needed before absolute clinical recommendations are founded...
  39. ncbi Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California 92093-0672, USA
    J Infect Dis 185:1409-16. 2002
    ..Thus, despite prolonged maintenance of undetectable levels of plasma HIV-1 RNA, HIV-1 DNA remains detectable in PBMC of children and may be a useful marker of further virus suppression...
  40. ncbi CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid
    Peter L Anderson
    Department of Pharmacy Practice, University of Colorado Health Sciences Center, Denver, USA
    Clin Pharmacol Ther 71:280-5. 2002
    ..We hypothesize this new finding may be associated with expression of P-glycoprotein...
  41. ncbi Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection
    Sibylle Grub
    F Hoffmann La Roche Ltd, Basel, Switzerland
    Clin Pharmacol Ther 71:122-30. 2002
    ....
  42. ncbi Longitudinal analysis of lymphocyte ratios and HIV-1 intracellular DNA levels in children
    Akihiko Saitoh
    Department of Pediatrics, Division of Infectious Diseases, University of California, San Diego, La Jolla, California 92093-0672, USA
    J Infect Dis 189:1216-20. 2004
    ..These data suggest that the increased proportion of naive lymphocytes found in children are less susceptible to HIV-1 infection than are the memory lymphocytes that dominate immune reconstitution in adults...
  43. ncbi Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:469-77. 2005
    ....
  44. ncbi Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects
    Ronald Swanstrom
    University of North Carolina Center for AIDS Research, University of North Carolina, Chapel Hill 27599, USA
    J Infect Dis 190:886-93. 2004
    ..This suggests that the prospective evaluation of PSS to identify regimens that maximize decreases in VL to reduce the probability of virologic rebound could improve antiretroviral treatment...
  45. ncbi An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children
    Akihiko Saitoh
    Division of Infectious Diseases, Department of Pediatrics, University of California, San Diego, La Jolla, California 92093 0672, USA
    AIDS 19:371-80. 2005
    ..This research examined the impact of single nucleotide polymorphisms (SNP) of MDR1 and CYP genes on nelfinavir and efavirenz pharmacokinetics and the response to highly active antiretroviral therapy (HAART) in HIV-1 infected children...
  46. ncbi Switch from ritonavir to indinavir in combination therapy for HIV-1-infected children
    Stephen I Pelton
    Boston Medical Center, Boston, MA 02118, USA
    Clin Infect Dis 40:1181-7. 2005
    ....
  47. ncbi Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:375-92. 2005
    ..In addition, the panel formulated a series of position statements that are relevant to the interpretation of current data and can aid the design of future clinical trials...
  48. ncbi A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
    Gary L Davis
    Division of Hepatology, Baylor University Medical Center, Dallas, TX 75246, USA
    Liver Transpl 11:941-9. 2005
    ..Further studies are required to determine whether the drug has beneficial effects in this group of patients...
  49. ncbi Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy
    Jennifer R King
    University of Alabama at Birmingham, School of Medicine, Division of Clinical Pharmacology, Birmingham, Alabama, USA
    AIDS 19:1059-63. 2005
    ..These data suggest that RTV affects IDV protein-binding characteristics and IDV also exhibits concentration dependent binding when administered with RTV...
  50. ncbi Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection
    Thomas B Campbell
    Division of Infectious Diseases, Department of Medicine, University of Colorado Health Sciences Center, Denver 80262, USA
    Clin Infect Dis 41:236-42. 2005
    ..Available data suggest that lamivudine contributes to partial viral suppression, despite the presence of M184V mutations and high-level phenotypic lamivudine resistance...
  51. ncbi Antiretroviral therapy for HIV-infected infants: progress and pitfalls
    Courtney V Fletcher
    AIDS 18:325-6. 2004
  52. ncbi Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda
    Laura A Guay
    Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    AIDS 16:1391-400. 2002
    ..Data suggest that a 400 mg/kg dose of HIVIGLOB would be the most appropriate dose for a subsequent efficacy trial of HIVIGLOB for the prevention of mother to child HIV transmission...
  53. ncbi Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children
    Courtney V Fletcher
    J Allergy Clin Immunol 119:747-50. 2007
  54. ncbi Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)
    William T Shearer
    J Allergy Clin Immunol 118:518-21. 2006
  55. ncbi Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions
    Rita B Effros
    David Geffen School of Medicine at the University of California, Los Angeles, USA
    Clin Infect Dis 47:542-53. 2008
    ..Answers to the questions posed are likely to help prioritize and balance strategies to slow the progression of HIV infection, to address comorbidities and drug toxicity, and to enhance understanding about both HIV infection and aging...